source
- FDA grants three-month extension for Capricor's Duchenne muscular dystrophy cell therapy reviewThe FDA has granted a three‑month extension to Capricor Therapeutics' review of its cell therapy for Duchenne muscular dystrophy after the original PDUFA date passed. The decision follows a content…
- FDA reportedly weighing two new deputy commissioner roles, one for health AI and one for drugsThe Food and Drug Administration is said to be considering the creation of two additional deputy commissioner positions. The proposal is being reported by media outlets but has not been confirmed b…